Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

At Retina World Congress, Patricio G. Schlottmann, MD, discussed investigational widefield OCTA platforms made by Chinese company TowardPi Medical.

By
Patricio G. Schlottmann, MD
Patricio G. Schlottmann, MD
May 14, 2026
2 min

Retinal Physician

1

Investigational OCTA devices show promise in detecting peripheral diabetic retinal disease.
2

Ultrawidefield OCTA can evaluate patients with diabetic retinopathy and macular edema.
3

These OCTA devices are not yet licensed in the U.S. but are used as investigational tools.
4

OCTA provides a non-invasive method for assessing disease progression without pupil dilation.
5

The technology captures 24-mm images in one go, aiding in the management of diabetic eye disease.

Original Source(s)

Retinal Physician

Investigational OCTA Devices Show Promise in Diabetic Disease Assessment

by Patricio G. Schlottmann, MD, Patricio G. Schlottmann, MD
May 14, 2026

Related Content

Retinal Physician

DME AWARE Study Defines Key Needs

Presenting results from the DME AWARE Delphi Study at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, Baruch D. Kuppermann, MD, PhD, director of the Gavin Herbert Eye Institute at the University of California, Irvine, described a set of consensus findings that point to unmet needs across the continuum of DME management, with particular emphasis on early intervention and noninvasive treatment options (Figure 1).